Cargando…

Toll-Like Receptor 9 Agonists for Cancer Therapy

The immune system has acquired increasing importance as a key player in cancer maintenance and growth. Thus, modulating anti-tumor immune mediators has become an attractive strategy for cancer treatment. Toll-like receptors (TLRs) have gradually emerged as potential targets of newer immunotherapies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Melisi, Davide, Frizziero, Melissa, Tamburrino, Anna, Zanotto, Marco, Carbone, Carmine, Piro, Geny, Tortora, Giampaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344222/ https://www.ncbi.nlm.nih.gov/pubmed/28548068 http://dx.doi.org/10.3390/biomedicines2030211

Ejemplares similares

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
por: Tamburrino, Anna, et al.
Publicado: (2013)

An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
por: Carbone, Carmine, et al.
Publicado: (2014)

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
por: Carbone, Carmine, et al.
Publicado: (2018)

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance
por: Cascetta, Priscilla, et al.
Publicado: (2018)

A circulating T(H)2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
por: Piro, Geny, et al.
Publicado: (2017)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
por: Chiaravalli, Marta, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
por: Cencioni, Chiara, et al.
Publicado: (2022)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus
por: Brannon, A. Rose, et al.
Publicado: (2016)

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification
por: Nasca, Vincenzo, et al.
Publicado: (2020)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Piro, G, et al.
Publicado: (2015)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo
por: Lupo, Francesca, et al.
Publicado: (2020)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue
por: Corogeanu, Diana, et al.
Publicado: (2023)

Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response
por: Piro, Geny, et al.
Publicado: (2021)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists
por: Meng, Wenjun, et al.
Publicado: (2011)

Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
por: Dongye, Zhangchi, et al.
Publicado: (2022)

EMT and Treatment Resistance in Pancreatic Cancer
por: Gaianigo, Nicola, et al.
Publicado: (2017)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

Toll-Like Receptor 9 in Breast Cancer
por: Sandholm, Jouko, et al.
Publicado: (2014)

Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy
por: Seth, Anushree, et al.
Publicado: (2016)

Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell
por: Girkin, Jason L.N., et al.
Publicado: (2022)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0a6890mqaqiipue76mirttdoul